Blog
RSS FeedPosted by Michael Wonder on 08 Oct 2018
Committee recommends against funding $250,000-a-year Orkambi cystic fibrosis drug
4 October 2018 - Canadian governments should not pay for a $250,000-a-year cystic fibrosis medication because it is not clear ...
Posted by Michael Wonder on 04 Oct 2018
Babies with spinal muscular atrophy to be covered for life-saving but costly Spinraza drug
3 October 2018 - Canadian children with a rare and often fatal neuromuscular disorder are about to gain public funding ...
Posted by Michael Wonder on 03 Oct 2018
Did Canada agree to a 'Trump veto' and costlier drugs in USMCA?
3 October 2018 - As trade experts look deeper into what exactly Canada signed onto as part of the United ...
Posted by Michael Wonder on 03 Oct 2018
Biogen Canada and pan-Canadian Pharmaceutical Alliance reach agreement on access to first and only approved treatment for spinal muscular atrophy in Canada
3 October 2018 - Biogen has resubmitted for a recommendation for broader access with updated clinical trial data. ...
Posted by Michael Wonder on 02 Oct 2018
Will USMCA affect Canada's drug prices? Depends on what happens next, experts say.
2 October 2018 - Trade deal extends 'data protection' period for expensive class of medicines to 10 years. ...
Posted by Michael Wonder on 22 Sep 2018
Ontario becomes first province to provide public funding of Tresiba for adults with diabetes mellitus
21 September 2018 - Manitoba to reimburse Tresiba following Ontario listing. ...
Posted by Michael Wonder on 10 Sep 2018
Canadian Dermatology Association and Canadian Society of Allergy and Clinical Immunology issue joint statement against the Canadian Agency for Drugs and Technologies in health recommendation
10 September 2018 - Many Canadian eczema sufferers are dealt a difficult blow; many patients face a future with no access ...
Posted by Michael Wonder on 09 Sep 2018
It's not just the EpiPen. Canada had 25 new drug shortages this week alone
8 September 2018 - Migraine and Parkinson's disease drugs and anesthetic among treatments added to drug shortage site. ...
Posted by Michael Wonder on 06 Sep 2018
We can make medicine affordable without the damage Pharmacare will cause Canadians
5 September 2018 - Governments should have public plans match the superior coverage offered in private drug plans and cover more ...
Posted by Michael Wonder on 30 Aug 2018
Renflexis (infliximab for injection) added to British Columbia's Provincial Drug Plan for all approved indications
22 August 2018 - Renflexis has been added to drug formulary for the treatment of adult and paediatric Crohn's disease and ...
Posted by Michael Wonder on 29 Aug 2018
B.C. to sue opioid makers for health care expenses of overdose crisis
29 August 2018 - The British Columbia Government will sue opioid manufacturers including Purdue Pharma in an effort to recoup ...
Posted by Michael Wonder on 28 Aug 2018
Ottawa’s drug-pricing changes threaten Canadians who suffer from rare diseases
28 August 2018 - The federal government’s plan to increasingly regulate the costs of pharmaceuticals could mean Canadians with cystic ...
Posted by Michael Wonder on 25 Aug 2018
Ensuring patient voices are heard: how patients can contribute to the CADTH Symposium
24 August 2018 - This webinar will outline the process for submitting abstracts and offer tips and ideas to increase the ...
Posted by Michael Wonder on 09 Aug 2018
New from CADTH: Pharmaceutical Reviews Update
9 August 2018 - CADTH is pleased to announce the launch of its new Pharmaceutical Reviews Update newsletter. ...
Posted by Michael Wonder on 09 Aug 2018
David Agnew appointed Chair of the CADTH Board of Directors
8 August 2018 - CADTH is pleased to announce the appointment of Mr. David Agnew to Chair of the CADTH ...